Two executive leaders from Eagle Pharmaceuticals Inc., a specialist in enhancing injectable medication products, will present at 11 a.m. Wednesday at the 35th annual J.P. Morgan Healthcare Conference in San Francisco.
CEO Scott Tarriff and Chief Financial Officer David Riggs of the Woodcliff Lake, New Jersey-based firm will speak at 11 a.m. Wednesday during the three-day California summit, slated to run through Thursday at San Francisco’s Westin St. Francis.
Tarriff’s and Riggs’ program is planned for immediate online public availability and will be accessible on Arena’s website at at www.eagleus.com under the Investors Section, both in real time and for 90 days following the event. It will also be available at http://jpmorgan.metameetings.com/confbook/healthcare17/directlink?p=22762.
Eagle Pharmaceuticals focuses on creating and marketing injectable products to overcome the limitations of similar existing systems as identified by physicians, pharmacists and other experts.
The firm operates under the regulatory oversight of the U.S. Food and Drug Administration, particularly its 505(b)(2) material providing guidance and instructions regarding new drug applications (NDA).
According to Camargo Pharmaceutical Services of Cinncinnati, which specializes in 505(b)(2) rules, the FDA’s 505(b)(2) is one of three strategies that pharmaceutical manufacturers can use for obtaining approval of new medication products.
“[The NDA] represents an appealing regulatory strategy for many clients,” Camargo said.
